Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604682 | 1.00 | HSD17B10 (0.38) | HSD17B10LMNAGAACRHBPCRHR2 | |
| SCHEMBL3605106 | 0.82 | GPBAR1 (0.36) | LMNAGPBAR1KDM4EMAPTPOLB | |
| SCHEMBL3610953 | 0.80 | CYP4F2 (0.37) | GPBAR1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL3614548 | 0.77 | GPBAR1 (0.32) | GPBAR1KDM4EMAPTPOLBSMN1; SMN2 | |
| SCHEMBL3610034 | 0.76 | SLC22A12 (0.43) | KDM4EMAPT | |
| SCHEMBL3618268 | 0.75 | GPBAR1 (0.41) | GPBAR1KDM4EMAPT | |
| SCHEMBL3603074 | 0.74 | ALDH1A1 (0.38) | HSD17B10LMNAGAAGPBAR1KDM4E | |
| SCHEMBL3603069 | 0.74 | ALDH1A1 (0.38) | HSD17B10LMNAGAAGPBAR1KDM4E | |
| SCHEMBL3605874 | 0.74 | CYP4F2 (0.42) | LMNAGPBAR1KDM4EPOLBSMN1; SMN2 | |
| SCHEMBL3605188 | 0.74 | CA2 (0.43) | HSD17B10GAAROCK2GPBAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128138-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | SLC5A1, SLC5A2, GLP1R | HSD17B10 390/4885LMNA 4306/4885GAA 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.